Clinical Trial Update: Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM) [NA]

View source ↗

Summary

A completed clinical trial evaluating whether glucagon-like peptide-1 (GLP-1) suppresses alpha cell secretion in type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Snippet

Sponsor: University Hospital, Gentofte, Copenhagen | Conditions: Hyperglycemia, Hyperglucagonemia | NA | Status: COMPLETED